Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Predictive role of homologous recombination deficiency (HRD) for irinotecan in combination with venadaparib, a novel PARP1/2 inhibitor, as third- or fourth-line treatment in patients with advanced gastric cancer.
Authors
Do-Youn Oh
Medical Oncology, Seoul National University Hospital, Seoul, South Korea
Do-Youn Oh , Min-Hee Ryu , Keun-Wook Lee , Sun Young Rha , Seung Tae Kim , Syma Iqbal , Jeesun Yoon , Hyung-Don Kim , Jin Won Kim , Ji-Won Kim , Won Sik Lee , Min Ju Hong , Myongjae Lee , Eun-Jihn Roh , KYOUNG SOO HA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT04725994
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 380)
DOI
10.1200/JCO.2024.42.3_suppl.380
Abstract #
380
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
First Author: Debra L. Richardson
First Author: Sarina Anne Piha-Paul
Poster
2024 ASCO Genitourinary Cancers Symposium
Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB).
First Author: Vineel Bhatlapenumarthi
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon